Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-10-05T16:33:32Z
Fecha de publicación2014-01-01
ResumenAmong the pharmacological strategies to treat obesity, two subtypes of the neuropeptide Y (NPY) receptor family have drawn the attention of several research groups in the effort to develop efficacious and safe anti-obesity drugs. In the last two decades, different classes of non-peptide compounds exhibiting significant anti-orexigenic responses in NPY knockout and NPY receptor deficient mice have been reported as NPY Y1 and Y5 receptor antagonists. At the beginning of this century, NPY receptor antagonists were considered promising anti-obesity compounds that modulate food intake and body weight in obese patients; however, only a few antagonists are currently being evaluated in clinical trials because there are other neuronal pathways that maintain homeostasis of food intake and body weight in animals, making the design of molecules with more affinity and selectivity for the NPY Y1 and Y5 receptors necessary. The present review is a compendium of the reports that account for the design, synthesis and biological evaluation of non-peptide compounds that selectively bind to NPY Y1 and Y5 receptors. This review presents a historic retrospective of those antagonists that have shown a high affinity and selectivity for these two NPY receptors in preclinical and clinical trials, highlighting key structural features that display more affinity, selectivity, and better pharmacokinetic profiles.es_ES
Doihttps://doi.org/10.2174/1389557514666141029233816es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/5343
Idiomaenes_ES
EditorialBENTHAM SCIENCE PUBL LTDes_ES
RelaciónMini-Reviews in Medicinal Chemistryes_ES
URL relacionadohttps://doi.org/10.2174/1389557514666141029233816es_ES
DerechosAcceso restringido / Suscripción (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_16eces_ES
FuenteMini-Reviews in Medicinal Chemistry
Palabra claveAnti-obesity drugses_ES
Palabra claveneuropeptide Yes_ES
Palabra claveNPY Y1 receptores_ES
Palabra claveNPY Y5 receptores_ES
Palabra clavenon-peptide antagonistses_ES
Palabra clavestructure-activity relationshipes_ES
TítuloNeuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Statuses_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorMoreno-Herrera, Antonio
AutorGarcia, Abraham
AutorPalos, Isidro
AutorRivera, Gildardo
AutorMoreno-Herrera, Antonioes_ES
AutorGarcia, Abrahames_ES
AutorPalos, Isidroes_ES
AutorRivera, Gildardoes_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número11es_ES
Rango de páginas896-919es_ES
URL relacionadahttps://doi.org/10.2174/1389557514666141029233816
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen14es_ES

Files

Collections

Documentación Cientifica